Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4086940 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Part A: LY4086940 Single Dose (Healthy Participants) | EXPERIMENTAL | Participants will receive a single dose of LY4086940 orally |
| Part A: Placebo Single Dose (Healthy Participants) | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo orally |
| Part A: LY4086940 Multiple Dose (Healthy Participants) | EXPERIMENTAL | Participants will receive LY4086940 orally for 3 days |
| Part A: Placebo Multiple Dose (Healthy Participants) | PLACEBO_COMPARATOR | Participants will receive placebo orally for 3 days |
| Part B: LY4086940 Multiple Dose (Participants with Overweight or Obesity) | EXPERIMENTAL | Participants will receive LY4086940 orally for 4 weeks |
| Part B: Placebo Multiple Dose (Participants with Overweight or Obesity) | PLACEBO_COMPARATOR | Participants will receive placebo orally for 4 weeks |
| Part C: LY4086940 Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity) | EXPERIMENTAL | Participants will receive LY4086940 orally for 4 weeks |
| Part C: Placebo Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity | PLACEBO_COMPARATOR | Participants will receive placebo orally for 4 weeks |
| Part D: LY4086940 Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity) | EXPERIMENTAL | Participants will receive LY4086940 orally for 4-6 weeks |
| Part D: Placebo Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity) | PLACEBO_COMPARATOR | Participants will receive placebo orally for 4-6 weeks |
| Part E (Open-Label): LY4086940 Single Dose (Healthy Participants) | EXPERIMENTAL | Participants will receive a single dose of LY4086940 intravenously (IV) |
| Name | Type | Description |
|---|---|---|
| LY4086940 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have no significant body weight change for the 3 months prior to screening Part A and Part E: * Are considered healthy * Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening Part B: * Have a BMI of 27 to 45 kg/m2 at screening Part C: *...
LY4086940 is an investigational small molecule being developed by Eli Lilly and Company for metabolic conditions. It is currently in Phase 1 clinical development. The drug has been studied in healthy participants and in participants with overweight or obesity, with or without type 2 diabetes.
LY4086940 is being studied for use in metabolic conditions, specifically in healthy participants and in participants with overweight or obesity, with or without type 2 diabetes. It is an investigational drug and has not been approved for any indication.
LY4086940 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical development.
LY4086940 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, and the drug is not currently in any active trials.
LY4086940 has been studied in one completed Phase 1 clinical trial, identified as NCT06945419. This trial enrolled 219 participants and was conducted in the United States and Singapore. The study was randomized, double-blind, and placebo-controlled.
LY4086940 is a unique investigational drug candidate developed by Eli Lilly and Company. It is not known to be the same as any other marketed or approved drug. It is currently in Phase 1 clinical development for metabolic conditions.